# A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer

> **NCT07059221** · PHASE1,PHASE2 · RECRUITING · sponsor: **Suzhou Suncadia Biopharmaceuticals Co., Ltd.** · enrollment: 96 (estimated)

## Conditions studied

- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** SHR-A2102
- **DRUG:** Adebrelimab
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT07059221
- **Lead sponsor:** Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-11
- **Primary completion:** 2026-03
- **Final completion:** 2028-03
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2025-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07059221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07059221, "A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07059221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*